Every Form 4 that Tandem Diabetes Care, Inc. (TNDM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TNDM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TNDM filings page.
Tandem Diabetes Care (TNDM) Chief Technology Officer Rick A. Carpenter reported several equity transactions involving company stock. He voluntarily disclosed acquiring 339 shares of common stock at $15.59 per share through the company’s Employee Stock Purchase Plan for the period from May 16, 2025 through November 17, 2025.
On the same date, 1,437 and 897 restricted stock units (RSUs) were converted into common shares at a $0 exercise price under the 2023 Long-Term Incentive Plan. To cover taxes on these RSU vestings, the company withheld 730 and 456 shares at a price of $18.61 per share, with no shares sold on the market. After these transactions, Carpenter directly beneficially owned 24,053 shares of Tandem Diabetes Care common stock.
Tandem Diabetes Care Inc. (TNDM) reported an insider equity transaction by its EVP & Chief Commercial Officer on a Form 4. On 11/17/2025, 76 restricted stock units (RSUs) were converted to common stock at an exercise price of $0, and 40 shares of common stock were withheld at $18.61 per share to cover tax obligations, with no shares sold on the market. Following these transactions, the officer beneficially owned 32,384 shares of common stock directly and 457 RSUs, subject to the company’s 2023 Long-Term Incentive Plan and a vesting schedule that runs in quarterly installments after an initial vesting on 5/15/2025.
Tandem Diabetes Care, Inc. (TNDM) executive vice president and chief operating officer Jean-Claude Kyrillos reported a routine purchase of company stock. On 11/17/2025, he acquired 160 shares of common stock at a price of $15.59 per share through the Tandem Diabetes Care Inc. Amended and Restated 2013 Employee Stock Purchase Plan for the ESPP purchase period from May 16, 2025 through November 17, 2025. Following this transaction, he beneficially owned 22,544 shares of Tandem Diabetes Care common stock held directly. The transaction is reported as exempt under Rule 16b-3(c), which typically covers certain employee benefit plan-related acquisitions.
Tandem Diabetes Care Inc. (TNDM) reported an insider equity transaction by EVP & Chief Financial Officer Leigh Vosseller on 11/17/2025. The filing shows the exercise of restricted stock units (RSUs), converting 1,503 and 1,496 RSUs into common shares at an exercise price of $0.
To cover tax withholding on these vestings, the company withheld 538 and 536 shares at a price of $18.61 per share, with no open-market sales taking place. After these transactions, Vosseller directly owned 37,648 shares of common stock and an additional 25,580 shares indirectly through the Leigh A. Vosseller Trust.
The Form 4 also notes remaining RSU awards under the company’s 2023 Long-Term Incentive Plan, which continue to vest over time based on previously established schedules.
Tandem Diabetes Care Inc. (TNDM) executive vice president and chief legal officer Shannon M. Hansen reported multiple equity transactions dated 11/17/2025 on a Form 4. Hansen voluntarily reported acquiring 800 shares of common stock through the company’s employee stock purchase plan for the May 16, 2025 to November 17, 2025 purchase period, a transaction noted as exempt under Rule 16b-3(c). Several restricted stock unit (RSU) awards were converted to common stock at a $0 exercise price, while 190, 515 and 393 shares were withheld by the company at $18.61 per share to cover tax obligations, with no market sales. After these transactions, Hansen directly holds 21,474 shares and indirectly holds 1,935 shares through the Shannon M. Hansen Trust.